Finance

Lists
JNJ:NYSE
Johnson & Johnson
$255.63
+2.00%
(+5.02) 1D
$256.19
+0.22% (+0.56)
After hours
Closed: Jul 22, 4:00:05 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for JNJ...
Open
$252.76
High
$256.29
Low
$251.21
Mkt. cap
615.36B
Avg. vol.
8.83M
Volume
0.00
Dividend
2.10%
Quarterly dividend
$1.34
Ex-dividend date
Aug 25, 2026
P/E ratio
29.64
52-wk high
$269.43
52-wk low
$164.23
EPS
$8.62
Beta
0.24
Shares outstanding
2.41B
No. of employees
138K
Open
$252.76
High
$256.29
Low
$251.21
Mkt. cap
615.36B
Avg. vol.
8.83M
Volume
0.00
Dividend
2.10%
Quarterly dividend
$1.34
Ex-dividend date
Aug 25, 2026
P/E ratio
29.64
52-wk high
$269.43
52-wk low
$164.23
EPS
$8.62
Beta
0.24
Shares outstanding
2.41B
No. of employees
138K
News stories
From sources across the web
Profile
Johnson & Johnson is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey. The company is ranked No. 48 on the 2025 Fortune 500 list of the largest United States corporations. In 2025, the company was ranked 42nd in the Forbes Global 2000. Along with Microsoft, Johnson & Johnson is one of only two U.S.-based companies that has a prime credit rating of AAA from S&P Global. Wikipedia
About Johnson & Johnson
CEOJoaquin Duato
Employees138K
FoundedJan 1886
HeadquartersNew Brunswick, New Jersey, United States
SectorPharmaceutical industry
Websitejnj.com
Analyst ratings
Based on 17 analysts giving stock ratings to JNJ in the past 3 months
Strong buy
Buy
13
Hold
4
Sell
0
12-month forecast
Based on 17 Wall Street analysts offering 12 month price targets for JNJ in the last 3 months.
Highest
Current $255.63
$305.00 (+19.31%)
Average
$279.19 (+9.22%)
Lowest
$255.00 (-0.25%)
Analyst
Recommendation
Action
Price target
Projected
Date
Trung Huynh
RBC Capital
Buy
Maintained
$287.00
+12.3%
07/21/2026
David Risinger
Leerink Partners
Buy
Maintained
$276.00
+8%
07/17/2026
Vamil Divan
Guggenheim
Buy
Maintained
$270.00
+5.6%
07/16/2026
Ilya Zubkov
Freedom Capital Markets
Buy
Upgraded
$280.00
+9.5%
07/16/2026
Jayson Bedford
Raymond James
Buy
Maintained
$265.00
+3.7%
07/16/2026
Louise Chen
Scotiabank
Buy
Maintained
$305.00
+19.3%
07/16/2026
Asad Haider
Goldman Sachs
Buy
Maintained
$282.00
+10.3%
07/16/2026
Chris Schott
J.P. Morgan
Hold
Reiterated
$270.00
+5.6%
07/16/2026
Terence Flynn
Morgan Stanley
Buy
Reiterated
$294.00
+15%
07/15/2026
Larry Biegelsen
Wells Fargo
Buy
Reiterated
$272.00
+6.4%
07/16/2026
Jason Gerberry
Bank of America Securities
Hold
Reiterated
$263.00
+2.9%
07/15/2026
Rick Wise
Stifel Nicolaus
Hold
Maintained
$260.00
+1.7%
07/15/2026
Shagun Singh Chadha
RBC Capital
Buy
Maintained
$287.00
+12.3%
07/13/2026
Steve Scala
TD Cowen
Buy
Maintained
$300.00
+17.4%
07/13/2026
Michael Nedelcovych
TD Cowen
Buy
Maintained
$300.00
+17.4%
07/13/2026
Joanne Wuensch
Citi
Buy
Maintained
$298.00
+16.6%
07/08/2026
Morten Herholdt
HSBC
Buy
Maintained
$290.00
+13.4%
07/06/2026
Matt Miksic
Barclays
Hold
Reiterated
$255.00
-0.2%
05/13/2026
Hans Engel
Erste Group
Buy
Maintained
-
-
05/05/2026
Josh Jennings
TD Cowen
Buy
Maintained
$250.00
-2.2%
04/23/2026
Lee Hambright
Bernstein
Hold
Maintained
-
-
04/14/2026
Danielle Antalffy
UBS
Buy
Reiterated
$280.00
+9.5%
03/17/2026
Nico Chen
DBS
Hold
Maintained
$240.00
-6.1%
02/24/2026
Last report
Jul 15, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$2.90 / $2.85
+1.59%beat
Revenue / Est. (USD)
25.31B / 25.06B
+0.99%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
23.99B
24.56B
24.06B
25.31B
Cost of goods sold
7.29B
7.81B
8.09B
8.00B
Cost of revenue
7.29B
7.81B
8.09B
8.00B
Research and development expenses
3.67B
4.25B
3.53B
3.65B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.78B
6.61B
5.85B
6.42B
Operating expense
9.46B
10.86B
9.38B
10.07B
Total operating expenses
16.75B
18.68B
17.47B
18.07B
Operating income
7.25B
5.89B
6.60B
7.24B
Other non operating income
17.00M
396.00M
-211.00M
237.00M
EBT including unusual items
7.49B
4.97B
5.99B
6.75B
EBT excluding unusual items
7.27B
6.03B
6.41B
7.42B
Income tax expense
2.34B
-150.00M
755.00M
1.21B
Effective tax rate
31.24%
-3.02%
12.60%
17.98%
Other operating expenses
-
-
-
-
Net income
5.15B
5.12B
5.24B
5.53B
Net profit margin
21.47%
20.83%
21.76%
21.86%
Earnings per share
2.80
2.46
2.70
2.90
Interest and investment income
227.00M
237.00M
229.00M
-
Interest expense
-245.00M
-214.00M
-272.00M
-62.00M
Net interest expenses
-18.00M
23.00M
-43.00M
-62.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
9.02B
7.90B
8.60B
9.24B
Gain or loss from assets sale
-57.00M
-132.00M
12.00M
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer